Sugi Predict

Sugi Predict / Compounds / SCHEMBL29638084

SCHEMBL29638084

SCHEMBL29638084

CSCC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)O)C(C)C

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ CALCR P30988 3/20 0.48
▸ TFPI P10646 4/20 0.44
▸ MC4R P32245 1/20 0.44
▸ MC5R P33032 1/20 0.44
▸ MC3R P41968 1/20 0.44
▸ MC1R Q01726 1/20 0.44
▸ CRHR1 P34998 1/20 0.43
▸ CRHR2 Q13324 1/20 0.43
▸ OPRM1 P35372 1/20 0.43
▸ OPRD1 P41143 1/20 0.43
▸ PTH1R Q03431 1/20 0.43
▸ APLNR P35414 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29616327 0.87 MC4R (0.52) CALCRTFPIMC4RMC5RMC3R
SCHEMBL31326910 0.87 MC4R (0.52) CALCRTFPIMC4RMC5RMC3R
SCHEMBL30019693 0.87 OPRD1 (0.48) CALCROPRD1APLNR
SCHEMBL29695402 0.84 NPY2R (0.46) CALCRTFPIOPRM1OPRD1
SCHEMBL31139067 0.84 CALCR (0.62) CALCRTFPIPTH1R
SCHEMBL30457049 0.84 OPRM1 (0.49) TFPIOPRM1OPRD1
SCHEMBL30883253 0.82 CALCR (0.63) CALCRTFPIAPLNR
SCHEMBL29479866 0.82 NPY2R (0.51) CALCRTFPIOPRD1
SCHEMBL31031614 0.82 CALCR (0.50) CALCRCRHR1CRHR2
SCHEMBL30456939 0.82 F2 (0.51) OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4591934-A2 VARIANTS OF C-TYPE NATRIURETIC PEPTIDE BioMarin Pharmaceutical Inc. (US) 2025-07-30 — — EP disclosed
EP-4523749-A2 VARIANTS OF C-TYPE NATRIURETIC PEPTIDE BioMarin Pharmaceutical Inc. (US) 2025-03-19 — — EP disclosed
US-12214015-B2 Use of c-type natriuretic peptide variants to treat osteoarthritis BIOMARIN PHARMACEUTICAL INC. (US) 2025-02-04 — — US disclosed
EP-4029512-A1 VARIANTS OF C-TYPE NATRIURETIC PEPTIDE BioMarin Pharmaceutical Inc. (US) 2022-07-20 — — EP disclosed
EP-4019038-A2 USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS BioMarin Pharmaceutical Inc. (US) 2022-06-29 — — EP disclosed
US-20220160836-A1 USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT OSTEOARTHRITIS BIOMARIN PHARMACEUTICAL INC. 2022-05-26 — — US disclosed
Send feedback